CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
4.87
3.18%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Savara Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 5.03
Open* 4.93
1-Year Change* 190%
Day's Range* 4.87 - 5.09
52 wk Range 1.63-4.97
Average Volume (10 days) 694.78K
Average Volume (3 months) 15.87M
Market Cap 577.91M
P/E Ratio -100.00K
Shares Outstanding 135.34M
Revenue N/A
EPS -0.31
Dividend (Yield %) N/A
Beta 0.78
Next Earnings Date Mar 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 5.03 -0.25 -4.73% 5.28 5.28 4.96
Apr 11, 2024 5.29 0.56 11.84% 4.73 5.29 4.73
Apr 10, 2024 4.69 0.02 0.43% 4.67 4.77 4.65
Apr 9, 2024 4.86 0.25 5.42% 4.61 4.89 4.58
Apr 8, 2024 4.65 -0.09 -1.90% 4.74 4.75 4.62
Apr 5, 2024 4.74 0.21 4.64% 4.53 4.78 4.49
Apr 4, 2024 4.57 -0.21 -4.39% 4.78 4.81 4.56
Apr 3, 2024 4.74 0.12 2.60% 4.62 4.78 4.57
Apr 2, 2024 4.63 -0.12 -2.53% 4.75 4.75 4.59
Apr 1, 2024 4.81 -0.13 -2.63% 4.94 4.94 4.77
Mar 28, 2024 4.94 0.10 2.07% 4.84 4.96 4.77
Mar 27, 2024 4.82 -0.08 -1.63% 4.90 4.93 4.80
Mar 26, 2024 4.87 0.04 0.83% 4.83 4.89 4.81
Mar 25, 2024 4.79 0.10 2.13% 4.69 4.87 4.68
Mar 22, 2024 4.77 -0.09 -1.85% 4.86 4.86 4.76
Mar 21, 2024 4.86 0.01 0.21% 4.85 4.95 4.85
Mar 20, 2024 4.85 0.07 1.46% 4.78 4.89 4.69
Mar 19, 2024 4.82 0.22 4.78% 4.60 4.85 4.60
Mar 18, 2024 4.68 0.04 0.86% 4.64 4.70 4.48
Mar 15, 2024 4.68 0.10 2.18% 4.58 4.75 4.58

Savara Events

Time (UTC) Country Event
Monday, May 13, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Savara Inc Earnings Release
Q1 2024 Savara Inc Earnings Release

Forecast

-

Previous

-
Friday, June 7, 2024

Time (UTC)

19:00

Country

US

Event

Savara Inc Annual Shareholders Meeting
Savara Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, August 8, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Savara Inc Earnings Release
Q2 2024 Savara Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0.257 0 0
Revenue 0 0.257
Total Operating Expense 38.839 41.477 49.557 79.025 70.045
Selling/General/Admin. Expenses, Total 10.929 12.35 14.264 13.081 10.654
Research & Development 27.879 28.991 35.038 38.781 37.173
Depreciation / Amortization 0.031 0.136 0.255 0.311 0.526
Unusual Expense (Income) 0 26.852 21.692
Operating Income -38.839 -41.477 -49.3 -79.025 -70.045
Interest Income (Expense), Net Non-Operating -0.107 -2.381 -1.208 -0.361 0.018
Other, Net 0.796 0.844 0.893 1.213 1.454
Net Income Before Taxes -38.15 -43.014 -49.615 -78.173 -68.573
Net Income After Taxes -38.15 -43.014 -49.615 -78.173 -61.516
Net Income Before Extra. Items -38.15 -43.014 -49.615 -78.173 -61.516
Net Income -38.15 -43.014 -49.615 -78.173 -61.516
Income Available to Common Excl. Extra. Items -38.15 -43.014 -49.615 -78.173 -61.516
Income Available to Common Incl. Extra. Items -38.15 -43.014 -49.615 -78.173 -61.516
Diluted Net Income -38.15 -43.014 -49.615 -78.173 -61.516
Diluted Weighted Average Shares 152.772 133.919 59.3091 40.0278 33.3007
Diluted EPS Excluding Extraordinary Items -0.24972 -0.32119 -0.83655 -1.95297 -1.84729
Diluted Normalized EPS -0.24972 -0.17185 -0.83655 -1.28214 -1.19589
Total Extraordinary Items
Total Adjustments to Net Income
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 12.221 12.112 10.875 10.535 9.383
Selling/General/Admin. Expenses, Total 3.302 3.366 3.242 2.376 2.957
Research & Development 8.911 8.738 7.626 8.151 6.418
Depreciation / Amortization 0.008 0.008 0.007 0.008 0.008
Operating Income -12.221 -12.112 -10.875 -10.535 -9.383
Interest Income (Expense), Net Non-Operating 0.742 0.794 0.574 0.144 -0.242
Other, Net 0.036 0.761 0.001 0.005 0.461
Net Income Before Taxes -11.443 -10.557 -10.3 -10.386 -9.164
Net Income After Taxes -11.443 -10.557 -10.3 -10.386 -9.164
Net Income Before Extra. Items -11.443 -10.557 -10.3 -10.386 -9.164
Net Income -11.443 -10.557 -10.3 -10.386 -9.164
Income Available to Common Excl. Extra. Items -11.443 -10.557 -10.3 -10.386 -9.164
Income Available to Common Incl. Extra. Items -11.443 -10.557 -10.3 -10.386 -9.164
Diluted Net Income -11.443 -10.557 -10.3 -10.386 -9.164
Diluted Weighted Average Shares 152.797 152.782 152.773 152.773 152.771
Diluted EPS Excluding Extraordinary Items -0.07489 -0.0691 -0.06742 -0.06798 -0.05999
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.07489 -0.0691 -0.06742 -0.06798 -0.05999
Revenue
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 128.954 165 85.121 124.067 113.344
Cash and Short Term Investments 125.876 161.171 82.188 121.761 110.83
Cash & Equivalents 52.1 34.012 22.88 49.804 24.301
Total Receivables, Net 0.954 1.144 1.695 1.617 1.684
Prepaid Expenses 2.053 2.329 1.044 0.431 0.723
Other Current Assets, Total 0.071 0.356 0.194 0.258 0.107
Total Assets 139.777 176.598 97.745 136.203 152.287
Property/Plant/Equipment, Total - Net 0.151 0.373 0.356 1.025 0.522
Goodwill, Net 26.918
Intangibles, Net 10.656 11.274 12.218 11.111 11.372
Other Long Term Assets, Total 0.016 -0.049 0.05 0.131
Total Current Liabilities 5.867 14.66 8.174 10.88 7.254
Accounts Payable 1.334 1.443 2.595 3.409 3.879
Accrued Expenses 4.533 4.884 5.579 5.471 3.058
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 8.333 2 0.041
Total Liabilities 31.999 32.1 33.362 34.505 44.068
Total Long Term Debt 26.078 17.323 25.104 23.112 24.53
Long Term Debt 26.078 17.323 25.104 23.112 24.53
Capital Lease Obligations 0
Deferred Income Tax 0
Other Liabilities, Total 0.054 0.117 0.084 0.513 12.284
Total Equity 107.778 144.498 64.383 101.698 108.219
Preferred Stock - Non Redeemable, Net
Common Stock 0.116 0.116 0.055 0.052 0.036
Additional Paid-In Capital 446.938 444.898 320.893 309.555 237.702
Retained Earnings (Accumulated Deficit) -338.671 -300.521 -257.507 -207.892 -129.719
Other Equity, Total -0.594 0.054 0.942 -0.017 0.2
Total Liabilities & Shareholders’ Equity 139.777 176.598 97.745 136.203 152.287
Total Common Shares Outstanding 114.046 114.037 54.153 50.7904 35.1461
Total Preferred Shares Outstanding
Short Term Investments 73.776 127.159 59.308 71.957 86.529
Property/Plant/Equipment, Total - Gross 2.074 2.452 2.329 2.699 1.89
Accumulated Depreciation, Total -1.923 -2.079 -1.973 -1.674 -1.368
Other Current Liabilities, Total 0 0.276
Unrealized Gain (Loss) -0.011 -0.049
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 170.096 107.9 117.626 128.954 137.069
Cash and Short Term Investments 168.251 105.179 114.777 125.876 134.077
Cash & Equivalents 27.69 22.745 33.984 52.1 119.841
Short Term Investments 140.561 82.434 80.793 73.776 14.236
Total Receivables, Net 0.951 1.001 1.04 0.954 0.861
Prepaid Expenses 0.732 1.561 1.571 2.053 2.029
Other Current Assets, Total 0.162 0.159 0.238 0.071 0.102
Total Assets 182.072 119.833 129.359 139.777 147.758
Property/Plant/Equipment, Total - Net 0.277 0.264 0.047 0.051 0.059
Intangibles, Net 10.497 10.781 10.818 10.656 9.754
Other Long Term Assets, Total 1.202 0.888 0.868 0.116 0.876
Total Current Liabilities 8.963 5.885 4.922 5.867 5.163
Accounts Payable 3.219 2.502 1.573 1.334 0.893
Accrued Expenses 5.744 3.383 3.349 4.533 4.27
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 35.528 32.118 31.104 31.999 31.244
Total Long Term Debt 26.281 26.213 26.145 26.078 26.01
Long Term Debt 26.281 26.213 26.145 26.078 26.01
Other Liabilities, Total 0.284 0.02 0.037 0.054 0.071
Total Equity 146.544 87.715 98.255 107.778 116.514
Common Stock 0.137 0.116 0.116 0.116 0.116
Additional Paid-In Capital 524.619 448.889 447.828 446.938 446.376
Retained Earnings (Accumulated Deficit) -377.27 -360.671 -349.228 -338.671 -328.371
Unrealized Gain (Loss) -0.062 -0.057 0.003 -0.011 -0.04
Other Equity, Total -0.88 -0.562 -0.464 -0.594 -1.567
Total Liabilities & Shareholders’ Equity 182.072 119.833 129.359 139.777 147.758
Total Common Shares Outstanding 135.34 114.15 114.065 114.046 114.043
Current Port. of LT Debt/Capital Leases 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -38.15 -43.014 -49.615 -78.173 -61.516
Cash From Operating Activities -34.554 -40.081 -39.836 -45.123 -39.275
Cash From Operating Activities 0.031 0.136 0.255 1.01 0.526
Deferred Taxes -7.057
Non-Cash Items 2.605 5.643 11.229 31.193 26.326
Cash Interest Paid 1.614 1.969 2.47 2.099 1.406
Changes in Working Capital 0.96 -2.846 -1.705 0.847 2.446
Cash From Investing Activities 52.645 -69.456 9.053 15.74 -13.619
Capital Expenditures -0.009 -0.057 -3.294 -0.148 -0.141
Other Investing Cash Flow Items, Total 52.654 -69.399 12.347 15.888 -13.478
Cash From Financing Activities 0.087 120.806 3.689 54.908 55.193
Financing Cash Flow Items -0.003 -0.078
Issuance (Retirement) of Stock, Net 0.002 120.884 4.203 54.949 46.374
Issuance (Retirement) of Debt, Net 0.088 0 -0.514 -0.041 8.819
Net Change in Cash 18.088 11.132 -26.924 25.503 2.18
Foreign Exchange Effects -0.09 -0.137 0.17 -0.022 -0.119
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -10.557 -38.15 -27.85 -17.464 -8.3
Cash From Operating Activities -12.026 -34.554 -25.903 -17.741 -8.425
Cash From Operating Activities 0.008 0.031 0.024 0.016 0.008
Non-Cash Items -0.006 2.605 2.258 1.636 1.04
Cash Interest Paid 0.464 1.614 1.186 0.857 0.484
Changes in Working Capital -1.471 0.96 -0.335 -1.929 -1.173
Cash From Investing Activities -6.095 52.645 111.856 78.86 53.665
Capital Expenditures -0.004 -0.009 -0.009 -0.005
Other Investing Cash Flow Items, Total -6.091 52.654 111.865 78.865 53.665
Cash From Financing Activities 0.026 0.087 0.086 0.087 -0.001
Issuance (Retirement) of Stock, Net 0.027 0.002 0 0 0
Issuance (Retirement) of Debt, Net 0.088 0.088 0.088
Foreign Exchange Effects -0.021 -0.09 -0.21 -0.065 -0.024
Net Change in Cash -18.116 18.088 85.829 61.141 45.215
Financing Cash Flow Items -0.001 -0.003 -0.002 -0.001 -0.001

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Savara Company profile

About Savara Inc

Savara Inc. is a clinical stage company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Savara Inc revenues decreased from $256K to $0K. Net loss decreased 12% to $31.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $20.4M (expense), Stock-based Compensation in SGA decrease of 51% to $1.5M (expense), Selling.

Equity composition

Common Stock $.001 Par, 12/11, 500M auth., 47,715,709 issd. Insiders own approx. 0.08% . IPO: N/A. PO: 11/02/06, 14,545,000 shs. @ $2.75 per share by ThinkEquity Partners LLC & Fortis Securities LLC. 04/10, 1-for-25 reverse split.

Industry: Bio Therapeutic Drugs

6836 Bee Cave Road
Building 3, Suite 201
AUSTIN
TEXAS 78746
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

XRP/USD

0.50 Price
+1.420% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,367.50 Price
+0.660% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0107%
Overnight fee time 21:00 (UTC)
Spread 0.50

BTC/USD

64,054.90 Price
+0.480% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

ETH/USD

3,109.08 Price
+1.720% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading